Promethazine

Promethazine is a first-generation, sedating antihistamine and a derivative of phenothiazine, the same chemical family as several antipsychotic drugs. Rather than being used as an antipsychotic, it is valued for its antihistamine, anti-sickness and sedative actions; pharmacologically it is a strong antagonist of the histamine H1 receptor, with additional blocking effects at muscarinic acetylcholine receptors and weaker activity at dopamine and other receptors ^[1].

The drug was synthesized in the 1940s by the French company Rhone-Poulenc and was approved for medical use in 1951. Marketed most familiarly as Phenergan, it has long since become a widely available generic medicine.

Promethazine is used across several areas: to relieve allergic conditions such as hay fever, to treat and prevent nausea and vomiting (including after surgery, during pregnancy and with motion sickness), to provide short-term sedation and to calm anxiety before procedures, and to ease some symptoms of the common cold. Its oral absorption is incomplete, at roughly a quarter of the dose, and it undergoes extensive first-pass metabolism in the liver, with an elimination half-life on the order of ten to fourteen hours ^[1].

The medicine is supplied as tablets, syrup, rectal suppositories and injectable solution. Several important safety issues shape its use. It is not recommended in children under two years of age because of a risk of severe, potentially fatal breathing problems. Given intravenously it can cause serious tissue damage and even gangrene if it escapes the vein, which led to a boxed warning and a preference for safer routes ^[3]. In overdose the most characteristic effect is delirium, the likelihood of which rises predictably with the dose taken ^[2]. Promethazine is also misused recreationally, notably combined with codeine cough syrup in the mixture known as purple drank, a practice that carries a risk of dangerous respiratory depression ^[4].

Promethazine is prescription and its most prominent effect is sedation, along with dry mouth, blurred vision, dizziness, and constipation from its anticholinergic action. It carries a boxed warning against use in children under two because of the risk of fatal respiratory depression, and another warning about severe tissue injury, including gangrene, if an injection leaks out of the vein or enters an artery, so intramuscular or carefully given deep intravenous routes are preferred. It adds to the effect of alcohol, opioids, and other sedatives, can rarely cause movement disorders or neuroleptic malignant syndrome, and should be used cautiously in older adults.

Promethazine combined with potassium chloride appears in drug interaction databases as a high-risk (class X) pairing, though the underlying mechanism lacks detailed mechanistic study in the published literature ^[7]. Promethazine's anticholinergic properties and central effects could theoretically potentiate gastrointestinal dysmotility caused by high-dose potassium, increasing ulceration risk, but robust case documentation is sparse.

Promethazine also has pharmacodynamic interactions with other central nervous system depressants (including morphine, benzodiazepines, and alcohol), compounding sedation and respiratory depression risk; however, these interactions are rarely isolated and documented formally as specific promethazine pairings in primary literature. The major gap is that promethazine's role in polydrug toxicity is often masked by the more prominent effects of opioids or benzodiazepines. Specific interactions with most modern antihistamines, atypical antipsychotics, and non-opioid analgesics remain undocumented in controlled studies.

Checking a whole stack? Run it through interactions + stacks.

Promethazine was synthesized in the late 1940s by chemists at the French company Rhône-Poulenc as part of the pioneering research into phenothiazine compounds, the same program that shortly afterward produced chlorpromazine and launched the modern era of psychiatric medicine. Introduced into clinical practice in the early 1950s and sold under names such as Phenergan, it was quickly adopted for allergy, nausea, motion sickness and sedation, drawing on its strong blockade of the histamine H1 receptor together with anticholinergic and mild antidopaminergic actions.

Over the following decades it became a familiar and inexpensive generic used across many fields of medicine, from anaesthesia to obstetrics. Its long clinical history has also delineated important safety boundaries; regulators later added strong warnings against its use in very young children because of the risk of severe respiratory depression, and cautions concerning intravenous administration and tissue injury. Promethazine remains a widely prescribed first-generation antihistamine to this day.

Promethazine is a familiar and dependable medicine, respected for its versatility across allergy, nausea, motion sickness and sedation. Anaesthesiologists and surgeons value it as an effective agent against postoperative nausea and vomiting; a randomized trial found a promethazine plus dexamethasone combination markedly reduced early nausea and vomiting after bariatric surgery, and large network analyses continue to place antihistamines like it among useful options for this common problem.

Its calming, anti-sickness action and low cost have kept it in steady use for more than seventy years. It is important to be candid about its limits: its strong sedative and anticholinergic effects, the firm warning against use in children under two, and cautions about intravenous injection mean it must be used thoughtfully. Handled with appropriate care, however, it remains a genuinely useful and time-tested drug.